扶脾活血化浊方药治疗酒精性脂肪肝的临床与实验研究
|
摘要
酒精性脂肪肝(AFL)是指因摄入酒精所引起的肝细胞内脂质蓄积超过肝湿重5%的肝损害性疾病,是临床最常见、最早期的酒精性肝病(ALD)之一。在我国,酒精引起的肝脏疾患已成为仅次于病毒性肝炎的第二大病因,而且随着人民生活水平的日益提高,饮酒人数的逐年增加,酒精性肝病有迅速增加趋势,已成为危害国民健康的又一严重疾病。现代医学治疗除了戒酒、对症治疗外,尚无特效的疗法。针对这种现状,我们在导师指导下,从四个方面较为详细而系统地研究和阐述了酒精性脂肪肝的理论、临床以及实验的问题。
第一部分为中医理论探讨。一是提出了酒精性脂肪肝的发生与身体禀赋,脾胃虚弱、饮酒过量、饮食不节等因素有关。其中素体不足、饮食不节等影响本病的发生、转归与预后,而饮酒过量是本病发生的直接原因。二是提出脾虚失运为本病发病的内在基础,痰瘀互结为本病发生的病理关键,认为饮食不节或饮酒过度,脾失健运,肝失疏泄,湿热蕴结脾胃,痰浊内生,气滞血瘀,最终导致气滞、痰湿、瘀血互结,积于胁下,病位在肝脾,与肾有关。其病机可概括为肝失疏泄,肝血瘀滞;脾失健运,湿邪不化,痰浊内生:肾气失化,痰瘀留滞等。三是提出了扶脾活血化浊为治疗大法,本病为本虚标实之证,应标本同治,治标之旨,应化浊祛瘀;治本之要,当扶脾益肾。
第二部分为临床研究。目的:观察消脂活血饮联合西利宾胺治疗酒精性脂肪肝(AFL)的临床效果。方法:将89例酒精性脂肪肝患者随机分成三组,其中中西药结合治疗组29例、中药组30例、西药组30例,三组病人在戒酒的基础上,辅以多种维生素口服,中西药结合组给予复方中药消脂活血饮和西利宾胺,中药组服用复方中药消脂活血饮;西药治疗组给予西利宾胺治疗,评价三组的疗效。结果:中西药结合组29例临床治愈12例,有效15例,无效2例,总有效率93.1%。中药组30例中临床治愈6例,有效12例,无效12例,总有效率60.0%。西药组30例中临床治愈6例,有效11例,无效13例,总有效率56.7%。三组有效率比较差异有显著性意义,P＜0.05。结论:消脂活血饮联合西利宾胺治疗酒精性脂肪肝,综合疗效优于单用西药和中药,具有明显改善临床症状和降低血脂的效果。
第三部分为实验研究。目的:探讨消脂活血饮联合西利宾胺治疗酒精性脂肪肝的机理。方法:建立酒精性脂肪肝大鼠模型,随机分为正常对照组、实验模型组、中药治疗组、西药治疗组和中西药结合组,分别给药后观察药物对模型大鼠血脂、肝体比、肝脏病理改变、胰岛素抵抗及瘦素的影响。结果:消脂活血饮联合西利宾胺能明显改善脂肪肝模型大鼠的肝脏病理情况,减轻肝脏的脂肪变性,降低血清中ALT、AST、TG和T-CH含量,降低体重,降低瘦素水平及改善胰岛素抵抗指数,且均明显优于单用中药或西药的治疗组。结论:消脂活血饮联合西利宾胺治疗酒精性脂肪肝的机理可能与其降低血脂,减少肝脏脂肪沉积,保护肝细胞,改善肝脏微循环有关。
第四部分为研究治疗进展。从中医和西医两个方面,对近年来众多学者和专家从不同角度研究和治疗酒精性脂肪肝进行了综述。现代医学治疗酒精性脂肪肝除了戒酒、对症治疗外,尚无特殊方法。中医药治疗酒精性脂肪肝,不论是分期治疗、辨证治疗或专药专方治疗,均有较好疗效,初步显示了其潜在优势,综合国内外酒精性脂肪肝的研究现状,目前中医中药治疗酒精性脂肪肝临床上缺乏对照大宗病例的前瞻性研究和现代医学检测手段(生化、免疫、B超甚至肝活检等);在实验研究方面亟待开发良好稳定的酒肝模型,观察指标比较单一,甚至重复、雷同等。因此尽快完善临床研究规范,深入开展实验研究,特别是细胞水平的研究,筛选临床重复性好、疗效高的方药,并进行药理药性研究,在此基础上提其有效成份,开展研究临床应用简便、高效的新剂型,是当前迫切需要开展的工作。
我们在扶脾活血化浊研究课题中,将89例研究样本按照中医症候分为脾虚湿痰型、湿热内结型、肝郁气滞型、气滞血瘀型、痰瘀互结型、阴虚热结型6型,结合B超检查情况,发现肝郁气滞型酒精性脂肪肝最多见,42例,占研究样本的47.2%,临床以轻度脂肪肝为主,占此型的57.1%;脾虚湿痰型次之,21例,占研究样本的23.6%,临床以中度脂肪肝为主,占此型的81.0%;痰瘀互结型10例,约占总数的11.2%,临床以重度脂肪肝为主,占此型的60%。以上三型占研究样本总数的82.0%。其他中医证型16例,所占比例较少。可见,绝大多数AFL患者辨证有脾虚、气滞、痰浊、瘀血病理因素存在。从临床疗效看,中药组30例临床治愈和有效的19例患者均为肝郁气滞证、脾虚湿痰证、湿热内结证、气滞血瘀证、痰瘀互结证,表明中药“消脂活血饮”具有疏肝健脾,化浊祛瘀的功效,主要适应证为肝郁气滞、脾虚湿痰、痰瘀互结型,尤其对AFL肝郁气滞、脾虚痰瘀兼夹的证患者临床疗效较好,而对其它证型疗效相对不理想,不是AFL的唯一治法。辨证论治是中医学之精髓,临证抓住AFL患者脾虚痰瘀这一基本病机演变规律,施以扶脾活血化浊之法,用中药“消脂活血饮”治疗取得了较好的临床疗效,这也揭示了中医临床辨证施治的重要性。
本研究为临床治疗提供了一种新的途径与方法,值得进一步研究和推广。
Alcoholic fatty liver (AFL) is the result of alcohol intake caused by lipid accumulation in liver cells more than 5% of liver wet weight of liver. it is the most common clinical For clinical treatment of this study provides a new way and method, is worthy of further research and extension. It is most early alcoholic liver disease (ALD) one. In China, alcohol-induced liver disease has become second cause of hepatitis, and along with increasing people's living standards, increasing the number of alcohol, alcoholic liver disease are rapidly increasing, it has become another serious public issue. In addition to modern medical treatment of alcoholism, there is no specific therapy without symptomatic treatment, In view of this status, under the guidance of our instructors, we research on alcoholic fatty liver theoretical, clinical and experimental problems. from the four aspects of a more detailed and systematic study.
The first part was to explore traditional Chinese medicine theory. Firstly, the alcohol made the occurrence of fatty liver and physical endowments, and also link to weak spleen and stomach, excessive drinking, diet and other factors. The weakness and diet irregularly may affect the occurrence of the disease, and the prognosis, while excessive drinking is the direct cause of this disease. Secondly, spleen deficiency and loss of transportation is the intrinsic disease-oriented basis, phlegm and blood stasis among pathological changes became the key to this disease, loss of health delivery spleen, liver qi catharsis deficiency, heat of spleen and stomach, endogenous phlegm, qi-stagnancy and blood stasis, which eventually led to stagnation of qi, phlegm, blood stasis, plot in flank, disease in the liver and spleen, and kidney-related. Its pathogenesis can be summarized as loss of liver qi catharsis, blood stasis; spleen dysfunction, Shenqi deficiency. Third, a help for the treatment of spleen Huazhuo Huoxue Dafa, the disease is asthenia in origin and not asthenia in superficiality, it surely should tonify spleen, activate blood circle and resolve the phlegm.
The second part of clinical research. Objective: To observe the effects of SilibinMeglumine Tablets with Xiaozhi Huoxue treating alcoholic fatty liver (AFL). Methods: 89 cases of alcoholic fatty liver patients were randomly divided into three groups, which combines group 1, Western and Chinese medicine treatment group 29 cases, group 2, 30 cases of Chinese medicine group, group 3, 30 cases of western medicine group, three groups of patients were received treatment combined with a variety of oral vitamin. Group1 with Western medicine and Huoxue Xiaozhi liquor, group2 was given Huoxue Xiaozhi alone; group3 SilibinMeglumine Tablets. And evaluate the efficacy of three groups. Results: The combination of Chinese and Western medicines clinically cured 29 cases of group 12 cases, 15 cases of effective and ineffective in 2 cases, total effective rate of 93.1%. Chinese medicine in 30 cases of group six cases of clinically cured, 12 cases of valid and invalid in 12 cases, total effective rate of 60.0%. Western medicine group of 30 cases of clinical cure in 6 cases, 11 cases of valid and invalid in 13 cases, total effective rate of 56.7%. Efficient compared three groups there was a significant difference significance, P <0.05. Conclusion: group1 was comprehensively effective than western medicine and Chinese medicine alone, with significant improvement in clinical symptoms and reduce the effects of blood lipids.
The third part is about experimental study. Objective: To investigate the mechanism of Xiaozhi Huoxue liquor combined with SilibinMeglumine treating alcoholic fatty liver. Methods: rats with alcoholic fatty liver were randomly divided into normal control group, the experimental model group, treatment group of Chinese medicine, Western medicine in the treatment group and western medicine combined group, respectively, observed rat serum lipids, liver body weight ratio liver pathological changes, insulin resistance and leptin. Results: SilibinMeglumine combined with Xiaozhi Huoxue liquor can improve liver pathological circumstances in fatty liver rat model, reducing liver steatosis, lowering serum ALT, AST, TG and T-CH content, lowering weight, lowering leptin levels and improving insulin resistance index, we found that there was significantly superior to traditional Chinese medicine or Western medicine alone in the treatment group. Conclusion: Xiaozhi Huoxue liquor combined with SilibinMeglumine may be related to lipid lowering to reduce liver fat deposition, protecting liver cells and improve the microcirculation of the liver.
The fourth part is about the progress of the treatment. From two aspects, Chinese medicine and Western medicine, in recent years many scholars and experts from different point of view and treatment of alcoholic fatty liver are reviewed. Modern medical treatment of alcoholic fatty liver in addition to alcohol, symptomatic treatment is concerned. Chinese medicine in treatment of alcoholic fatty liver, regardless of the treatment is implemented uptodate, differentiation or post-treatment drug treatment professionals have better efficacy, the initial indications of its potential advantages, comprehensive domestic and foreign alcoholic fatty liver study of the status, the current Chinese medicine alcoholic fatty liver treatment of clinical cases is lack of the bulk of the forward-looking research and methods of modern medical science (biochemistry, immunology, B-and even liver biopsy, etc.); in experimental studies it is need to develop a stable good wine liver model, compared observed single, or even repeat the same and so on. Therefore improving the clinical research norms as soon as possible, in-depth research carried out experiments, in particular the cellular level of research, clinical screening of good reproducibility, high efficacy of herbs and herbal pharmacology studies, on the basis of their active ingredients mentioned, simple clinical application of research and efficient new forms, is an urgent need for work.
In our project of Huazhuo Huoxue tonifying spleen research, 89 cases in accordance with traditional Chinese medicine is divided into deficiency syndrome of phlegm and damp, heat and humid, stagnation of liver Qi, stagnation of Qi and blood stasis,phlegm and blood stasis, Yin deficiency. combined with B-ultrasound, we found that stagnation of liver Qi stagnation is the most prevalent, which 42 cases of alcoholic fatty liver, accounting for 47.2 percent. mild fatty liver, accounting for 57.1% of this type; syndrome of spleen deficiency and phlegm damp followed by 21 cases, accounting for 23.6 percent of the sample, moderate fatty liver, accounting for 81.0% of this type; syndrome of phlegm and blood stasis 10 cases, accounting for 11.2 percent of the total number, clinical to severe fatty liver, accounting for 60% of this type. All the cases accounted for more than 82.0 percent of the total number of samples. Other 16 cases, the less proportion. This shows that the vast majority of patients with AFL have a spleen deficiency Syndrome, Qi stagnation, phlegm, blood stasis disease factors. From the clinical efficacy, 19 cases in group 1 with effective fell into syndrome of liver depression qi stagnation, spleen phlegm and damp, hot and humid, liver qi stagnation and blood stasis, phlegm and blood stasis that traditional Chinese medicine "Xiaozhi Huoxue liquor" with loosening liver qi and tonifying spleen, Huazhuo Quyu effectiveness, the main indication for liver depression qi stagnation, spleen damp and phlegm, phlegm and blood stasis of AFL in particular, stagnation of liver Qi stagnation, blood stasis and spleen deficiency clinical efficacy in patients were good, and the effect of other type was not ideal. Treatment is of the essence of Chinese medicine, seizing the AFL in patients with clinical deficiency blood stasis of the basic pathogenesis of the evolution of the law, help to expose the Huazhuo Huoxue tonifying spleen, using traditional Chinese medicine to obtain a better clinical efficacy. This also prompted the importance of diagnosis.
For clinical treatment, this study provides a new way and method, is worthy of further research and extension.
第一部分为中医理论探讨。一是提出了酒精性脂肪肝的发生与身体禀赋,脾胃虚弱、饮酒过量、饮食不节等因素有关。其中素体不足、饮食不节等影响本病的发生、转归与预后,而饮酒过量是本病发生的直接原因。二是提出脾虚失运为本病发病的内在基础,痰瘀互结为本病发生的病理关键,认为饮食不节或饮酒过度,脾失健运,肝失疏泄,湿热蕴结脾胃,痰浊内生,气滞血瘀,最终导致气滞、痰湿、瘀血互结,积于胁下,病位在肝脾,与肾有关。其病机可概括为肝失疏泄,肝血瘀滞;脾失健运,湿邪不化,痰浊内生:肾气失化,痰瘀留滞等。三是提出了扶脾活血化浊为治疗大法,本病为本虚标实之证,应标本同治,治标之旨,应化浊祛瘀;治本之要,当扶脾益肾。
第二部分为临床研究。目的:观察消脂活血饮联合西利宾胺治疗酒精性脂肪肝(AFL)的临床效果。方法:将89例酒精性脂肪肝患者随机分成三组,其中中西药结合治疗组29例、中药组30例、西药组30例,三组病人在戒酒的基础上,辅以多种维生素口服,中西药结合组给予复方中药消脂活血饮和西利宾胺,中药组服用复方中药消脂活血饮;西药治疗组给予西利宾胺治疗,评价三组的疗效。结果:中西药结合组29例临床治愈12例,有效15例,无效2例,总有效率93.1%。中药组30例中临床治愈6例,有效12例,无效12例,总有效率60.0%。西药组30例中临床治愈6例,有效11例,无效13例,总有效率56.7%。三组有效率比较差异有显著性意义,P＜0.05。结论:消脂活血饮联合西利宾胺治疗酒精性脂肪肝,综合疗效优于单用西药和中药,具有明显改善临床症状和降低血脂的效果。
第三部分为实验研究。目的:探讨消脂活血饮联合西利宾胺治疗酒精性脂肪肝的机理。方法:建立酒精性脂肪肝大鼠模型,随机分为正常对照组、实验模型组、中药治疗组、西药治疗组和中西药结合组,分别给药后观察药物对模型大鼠血脂、肝体比、肝脏病理改变、胰岛素抵抗及瘦素的影响。结果:消脂活血饮联合西利宾胺能明显改善脂肪肝模型大鼠的肝脏病理情况,减轻肝脏的脂肪变性,降低血清中ALT、AST、TG和T-CH含量,降低体重,降低瘦素水平及改善胰岛素抵抗指数,且均明显优于单用中药或西药的治疗组。结论:消脂活血饮联合西利宾胺治疗酒精性脂肪肝的机理可能与其降低血脂,减少肝脏脂肪沉积,保护肝细胞,改善肝脏微循环有关。
第四部分为研究治疗进展。从中医和西医两个方面,对近年来众多学者和专家从不同角度研究和治疗酒精性脂肪肝进行了综述。现代医学治疗酒精性脂肪肝除了戒酒、对症治疗外,尚无特殊方法。中医药治疗酒精性脂肪肝,不论是分期治疗、辨证治疗或专药专方治疗,均有较好疗效,初步显示了其潜在优势,综合国内外酒精性脂肪肝的研究现状,目前中医中药治疗酒精性脂肪肝临床上缺乏对照大宗病例的前瞻性研究和现代医学检测手段(生化、免疫、B超甚至肝活检等);在实验研究方面亟待开发良好稳定的酒肝模型,观察指标比较单一,甚至重复、雷同等。因此尽快完善临床研究规范,深入开展实验研究,特别是细胞水平的研究,筛选临床重复性好、疗效高的方药,并进行药理药性研究,在此基础上提其有效成份,开展研究临床应用简便、高效的新剂型,是当前迫切需要开展的工作。
我们在扶脾活血化浊研究课题中,将89例研究样本按照中医症候分为脾虚湿痰型、湿热内结型、肝郁气滞型、气滞血瘀型、痰瘀互结型、阴虚热结型6型,结合B超检查情况,发现肝郁气滞型酒精性脂肪肝最多见,42例,占研究样本的47.2%,临床以轻度脂肪肝为主,占此型的57.1%;脾虚湿痰型次之,21例,占研究样本的23.6%,临床以中度脂肪肝为主,占此型的81.0%;痰瘀互结型10例,约占总数的11.2%,临床以重度脂肪肝为主,占此型的60%。以上三型占研究样本总数的82.0%。其他中医证型16例,所占比例较少。可见,绝大多数AFL患者辨证有脾虚、气滞、痰浊、瘀血病理因素存在。从临床疗效看,中药组30例临床治愈和有效的19例患者均为肝郁气滞证、脾虚湿痰证、湿热内结证、气滞血瘀证、痰瘀互结证,表明中药“消脂活血饮”具有疏肝健脾,化浊祛瘀的功效,主要适应证为肝郁气滞、脾虚湿痰、痰瘀互结型,尤其对AFL肝郁气滞、脾虚痰瘀兼夹的证患者临床疗效较好,而对其它证型疗效相对不理想,不是AFL的唯一治法。辨证论治是中医学之精髓,临证抓住AFL患者脾虚痰瘀这一基本病机演变规律,施以扶脾活血化浊之法,用中药“消脂活血饮”治疗取得了较好的临床疗效,这也揭示了中医临床辨证施治的重要性。
本研究为临床治疗提供了一种新的途径与方法,值得进一步研究和推广。
Alcoholic fatty liver (AFL) is the result of alcohol intake caused by lipid accumulation in liver cells more than 5% of liver wet weight of liver. it is the most common clinical For clinical treatment of this study provides a new way and method, is worthy of further research and extension. It is most early alcoholic liver disease (ALD) one. In China, alcohol-induced liver disease has become second cause of hepatitis, and along with increasing people's living standards, increasing the number of alcohol, alcoholic liver disease are rapidly increasing, it has become another serious public issue. In addition to modern medical treatment of alcoholism, there is no specific therapy without symptomatic treatment, In view of this status, under the guidance of our instructors, we research on alcoholic fatty liver theoretical, clinical and experimental problems. from the four aspects of a more detailed and systematic study.
The first part was to explore traditional Chinese medicine theory. Firstly, the alcohol made the occurrence of fatty liver and physical endowments, and also link to weak spleen and stomach, excessive drinking, diet and other factors. The weakness and diet irregularly may affect the occurrence of the disease, and the prognosis, while excessive drinking is the direct cause of this disease. Secondly, spleen deficiency and loss of transportation is the intrinsic disease-oriented basis, phlegm and blood stasis among pathological changes became the key to this disease, loss of health delivery spleen, liver qi catharsis deficiency, heat of spleen and stomach, endogenous phlegm, qi-stagnancy and blood stasis, which eventually led to stagnation of qi, phlegm, blood stasis, plot in flank, disease in the liver and spleen, and kidney-related. Its pathogenesis can be summarized as loss of liver qi catharsis, blood stasis; spleen dysfunction, Shenqi deficiency. Third, a help for the treatment of spleen Huazhuo Huoxue Dafa, the disease is asthenia in origin and not asthenia in superficiality, it surely should tonify spleen, activate blood circle and resolve the phlegm.
The second part of clinical research. Objective: To observe the effects of SilibinMeglumine Tablets with Xiaozhi Huoxue treating alcoholic fatty liver (AFL). Methods: 89 cases of alcoholic fatty liver patients were randomly divided into three groups, which combines group 1, Western and Chinese medicine treatment group 29 cases, group 2, 30 cases of Chinese medicine group, group 3, 30 cases of western medicine group, three groups of patients were received treatment combined with a variety of oral vitamin. Group1 with Western medicine and Huoxue Xiaozhi liquor, group2 was given Huoxue Xiaozhi alone; group3 SilibinMeglumine Tablets. And evaluate the efficacy of three groups. Results: The combination of Chinese and Western medicines clinically cured 29 cases of group 12 cases, 15 cases of effective and ineffective in 2 cases, total effective rate of 93.1%. Chinese medicine in 30 cases of group six cases of clinically cured, 12 cases of valid and invalid in 12 cases, total effective rate of 60.0%. Western medicine group of 30 cases of clinical cure in 6 cases, 11 cases of valid and invalid in 13 cases, total effective rate of 56.7%. Efficient compared three groups there was a significant difference significance, P <0.05. Conclusion: group1 was comprehensively effective than western medicine and Chinese medicine alone, with significant improvement in clinical symptoms and reduce the effects of blood lipids.
The third part is about experimental study. Objective: To investigate the mechanism of Xiaozhi Huoxue liquor combined with SilibinMeglumine treating alcoholic fatty liver. Methods: rats with alcoholic fatty liver were randomly divided into normal control group, the experimental model group, treatment group of Chinese medicine, Western medicine in the treatment group and western medicine combined group, respectively, observed rat serum lipids, liver body weight ratio liver pathological changes, insulin resistance and leptin. Results: SilibinMeglumine combined with Xiaozhi Huoxue liquor can improve liver pathological circumstances in fatty liver rat model, reducing liver steatosis, lowering serum ALT, AST, TG and T-CH content, lowering weight, lowering leptin levels and improving insulin resistance index, we found that there was significantly superior to traditional Chinese medicine or Western medicine alone in the treatment group. Conclusion: Xiaozhi Huoxue liquor combined with SilibinMeglumine may be related to lipid lowering to reduce liver fat deposition, protecting liver cells and improve the microcirculation of the liver.
The fourth part is about the progress of the treatment. From two aspects, Chinese medicine and Western medicine, in recent years many scholars and experts from different point of view and treatment of alcoholic fatty liver are reviewed. Modern medical treatment of alcoholic fatty liver in addition to alcohol, symptomatic treatment is concerned. Chinese medicine in treatment of alcoholic fatty liver, regardless of the treatment is implemented uptodate, differentiation or post-treatment drug treatment professionals have better efficacy, the initial indications of its potential advantages, comprehensive domestic and foreign alcoholic fatty liver study of the status, the current Chinese medicine alcoholic fatty liver treatment of clinical cases is lack of the bulk of the forward-looking research and methods of modern medical science (biochemistry, immunology, B-and even liver biopsy, etc.); in experimental studies it is need to develop a stable good wine liver model, compared observed single, or even repeat the same and so on. Therefore improving the clinical research norms as soon as possible, in-depth research carried out experiments, in particular the cellular level of research, clinical screening of good reproducibility, high efficacy of herbs and herbal pharmacology studies, on the basis of their active ingredients mentioned, simple clinical application of research and efficient new forms, is an urgent need for work.
In our project of Huazhuo Huoxue tonifying spleen research, 89 cases in accordance with traditional Chinese medicine is divided into deficiency syndrome of phlegm and damp, heat and humid, stagnation of liver Qi, stagnation of Qi and blood stasis,phlegm and blood stasis, Yin deficiency. combined with B-ultrasound, we found that stagnation of liver Qi stagnation is the most prevalent, which 42 cases of alcoholic fatty liver, accounting for 47.2 percent. mild fatty liver, accounting for 57.1% of this type; syndrome of spleen deficiency and phlegm damp followed by 21 cases, accounting for 23.6 percent of the sample, moderate fatty liver, accounting for 81.0% of this type; syndrome of phlegm and blood stasis 10 cases, accounting for 11.2 percent of the total number, clinical to severe fatty liver, accounting for 60% of this type. All the cases accounted for more than 82.0 percent of the total number of samples. Other 16 cases, the less proportion. This shows that the vast majority of patients with AFL have a spleen deficiency Syndrome, Qi stagnation, phlegm, blood stasis disease factors. From the clinical efficacy, 19 cases in group 1 with effective fell into syndrome of liver depression qi stagnation, spleen phlegm and damp, hot and humid, liver qi stagnation and blood stasis, phlegm and blood stasis that traditional Chinese medicine "Xiaozhi Huoxue liquor" with loosening liver qi and tonifying spleen, Huazhuo Quyu effectiveness, the main indication for liver depression qi stagnation, spleen damp and phlegm, phlegm and blood stasis of AFL in particular, stagnation of liver Qi stagnation, blood stasis and spleen deficiency clinical efficacy in patients were good, and the effect of other type was not ideal. Treatment is of the essence of Chinese medicine, seizing the AFL in patients with clinical deficiency blood stasis of the basic pathogenesis of the evolution of the law, help to expose the Huazhuo Huoxue tonifying spleen, using traditional Chinese medicine to obtain a better clinical efficacy. This also prompted the importance of diagnosis.
For clinical treatment, this study provides a new way and method, is worthy of further research and extension.
引文
[1]范建高,朱军,李新建,等.上海市成人脂肪肝患病率及其危险因素流行病学调查[J].中华肝脏病杂志,2005,13(2):87
[2]厉有名,陈卫星,虞朝辉,等.浙江省酒精性肝病流行病学调查慨况[J].中华肝脏病杂志,2003,11(11):649
[3]施军平,邬菊英,潘红英,等.酒精性脂肪肝患者血浆ET、TNF-a水平变化及临床意义[J].浙江中医学院学报,2002,26(3):26
[4]范建高.酒精性与非酒精性脂肪性肝病[J].中华肝脏病杂志,2003.11(11):692
[5]M cCullough AJ,O,Connor JF.Alcoholic liver disease:proposed recommendations for the American Collrge of Gastroenterology.AM J Gastroenol 1998;93:2022-2036
[6]王炳元,傅宝玉教授.酒精性肝病的诊断与治疗[J].中华肝脏病杂,2001.9(5):313
[7]李俊峰,杨冬华.非酒精性脂肪性肝病的药物治疗[J].临床荟萃,2004,19(22):1304-1306
[8]Chawla Rk,Hussaim.S,Watson WH,et al.Effect of Ethanol Consumption on Metabolism of SAMe in Rat Liver,Druu Invest,1992,4(Suppl4):S41
[9]河福全,贲长恩,王德福等.小柴胡汤对大鼠酒精性肝病防护作用的组化和生化研究[J].北京中医药大学学报,1997,20(1):45-47
[10]张茂信.搜剔通络为主治疗早期肝硬变腹水24例[J].湖北中医杂志.1996,18(3):42
[11]常惟智.中医药治疗脂肪肝研究进展概况[J].中医药学报.2005,33(3):64-66
[12]孔祥廉.脂肪肝的中医治疗[M].中国中医药出版社.85页
[1]叶永安.酒精性肝病中医认识初探[J].中国医药学报,1997:12(5):8-10
[2]金容炫,张浩,田德禄.田德禄教授治疗酒精性肝病的临床验[J].中国中医基础医学杂志,2003;9(8):66-67
[3]欧琴.酒精性肝病中医药研究进展[J].河北中医,2002;24(11):870-871
[4]任延明.酒精性肝病的中医病机浅探[J].青海医学院学报,2004;25(2):140-141
[5]华一利,陈建伟,吴惫平,等.明党参降血脂作用的实脸研究[J],南京中医学院学报,1994.10(4):31
[6]吴惫平,陶学勤,陈建伟,等.明党参不同提取物对大鼠肝匀浆上清液生成脂质过权化物的影响[J].南京中医学院学报,1993.9(1):26
[7]吴惫平,华一利,席蓓润,等.明党参在大鼠高胆固醉血症中扰载化作用[J].南京中医学院学报,1994.10(4):33
[8]李素婷,齐洁敏,杨鹤梅,等.柴胡总提物对大鼠酒精性肝损伤的保护作用[J].承德医学院学报,2007,24(1):9-10
[9]李芳,李建北,张东明.柴胡的药理研究进展[J].时珍国医国药,2004;15(2):120-121.
[10]邵淑丽.柴胡、姜黄对小白鼠实验性高脂血症的预防作用[J].中医药学报,2002;30(4):59-59。
[11]蒋天佑.白术的研究进展[J].中医药研究,2004,6(5):59
[12]邹祖绳.中医研究员资料汇刊(第一辑)[J],上海科学技术出版社,1996,13(5):26
[13]毛俊浩,吕志良,曾群力,等.白术糖对小鼠淋巴细胞功能的调节[J].免疫学杂志,1996,12(4):233
[14]陈岳祥,李石,范列英,等.丹参单体I H7643抗肝纤维化作用的实验研究[J].中华医学杂志,1998,76(8):636
[15]吕冰,陈红旗,赵勇刚,等.丹参治疗重型颅脑损伤的临床应用[J].医师进修杂志,1999,22(1):19
[16]戚心广,稻田丰.丹参、赤芍对实验性肝损伤肝细胞保护作用的机理研究[J].中国中西医结合杂志,1991,11(2):102
[17]孙克勤,李素芝,刘厚东,等.丹参对高原大鼠缺血再灌注损伤的保护作用[J].中国民间医学杂志,2005,17(1):10-11
[18]王树立,李永德,赵勤,等.山碴、黄茂及刺五加对豚鼠胆固醇代谢的影响[J].中国中西医结合杂志,2007,7(8):483
[19]翁维良.降血脂中草药研究进展[J].天津中医,2006,3(1):34
[20]王伟,陈文为.从抗氧化反应探讨“药食同源”的含义[J].中西医结合杂志,2004,11(3):159
[21]崔香玉.决明子乙醇提取物对大鼠急性肝损伤的保护作用[J].延边大学医学学报,2006,29(4):244-246
[22]林冬静,金政.决明子提取物对急性肝损伤保护作用的实验研究[J].时珍国医国药,2006,17(2):214-215
[23]任秀兰.重用赤芍治疗肝病重度黄疸[J].山西中医,2000;(5):10
[24]胡梅雪.活血化瘀法治疗肝纤维化[J].中医药学报,1998;(2):13
[25]黄孔威,傅乃武.赤芍对免疫功能的影响[J].药学通报,1982;17(10):54.
[26]戚心广.丹参、赤芍对实验性肝损伤肝细胞保护作用的机理研究[J].中西医结合杂志,1991:11(2):102
[27]张希恩,王利华.大黄保肝利胆作用的药理与临床[J].中医药研,1995;(4):56
[28]胡林华,等.生大黄的实验研究及肝性昏迷的临床观察[J].江苏医药,1994;20(6):304
[29]焦东海,等.精制大黄片治疗急性病毒性肝炎的研究[J].中医杂志,1990;31(9): 35
[30]YUANGohua,WEIJin,ZHOUJingguo,etal.Aoptosis of Human Hepatoma Cells Induced by Gynstemma Pentaphyllum Makino[J].The Chinese German Journal of Clinical On cology,2006,5(3):173-177
[31]陈几香,张建国,张莉,等绞股蓝总皂苷保肝作用实验研究[J]中国药业,2007,16(13):7-8
[32]ChenJC,TsaiCC,ChenLD,etal.Am Therapeutic effect of gypenoside on chronic liver injury and fibrosis induced by CC14 inrats[J]JchinMed,2000,28(2):175-185
[33]何冬宁,等.牡蛎提取营养液对大剂量CC14致小鼠急性肝损伤的保护作用[J].中国公共卫生学报,1997,16(3):152
[34]范建高,等.牛磺酸、金牡蛎对大鼠酒精性肝损伤的防治作用[J].中华肝脏病杂志,1999,4(3):154)
[35]罗琼,阎俟,李瑾玮,等.枸杞及其多糖对家免血脂的影响[J]营养学报,1997,19(2):415-418
[36]衣艳君.枸杞降血脂作用的实验研究[J].首都师范大学学报(自然科学版),2000,21(4):68-70
[37]闫秀英,许志华,韩丽莎,等.枸杞子对四氯化碳致大鼠肝脂类过氧化作用的抑制[J].包头医学院学报,1998;14(1):7-8
[38]边纶,沈新生,王燕蓉,等.枸杞多糖对四氯化碳所致小鼠肝损伤修复作用的形态学研究[J].宁夏医学杂志,1996;18(4):196-198
[39]白秀珍,王文忠,赵东.首乌、黄芪、天麻对血清羟脯氨酸含量影响的实验研究[J].锦州医学院学报,1994,15(1):27,80
[40]Wijaya-E,Wu-Z-M,Ng-F.Effect of Slimax',a Chinese herbal mixture,on obesity[J].INT-J-PHARMACOGN,1995,33(1):41-46
[41]李丽春,吴晓东,田维熙.何首乌提取物对脂肪酸合酶的抑制作用[J].中国生物化学与分子生物学报,2003,19(3):297-304
[42]刘成基,张清华,林军.炮制何首乌对小鼠实验性肝损伤后肝脂代谢的影响[J].中国中药杂志,1992,17(10):595-596
[43]金国琴,赵伟康.首乌制剂对老年大鼠胸腺、肝脏蛋白质和核酸含量的影响[J].中草药,1994,25(11):590-491,589
[44]HanYO,HanMJ,ParkSH,etal.Protective effeets ofkakkalide from Flos Puerariae on ethano-induced lethality and hepatic injury are dependent on its biotransformation by human intestinal microflora[J].J Pharmacol Sci,2003,93(3):331-336
[45]Ni iho Y,YamaZaki T,Nakajima Y,etal.Pharmacological studies on Puerariae Flos.I.The effeets of Puerariae Flos on alcoholic metabolism and spontaneous movement in mice[J].Yakugaku Zasshi,1989,109(6):424
[46]田代华.实用中药辞典(下卷)[M].北京:人民卫生出版社,2002,1897.
[47]芦洁,李文哲,倪亚明.中药水提取物对乙醇脱氢酶活性影响的初步研究[J].同济大学学报医学版,2002,23(1):23
[1]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南(2006年2月修订)[J].现代消化及介入诊疗,2007,(4):268-270
[2]郑筱萸.中药新药临床研究指导原则[M].中国医药科技出版社,2002:361-383
[3]吴俊芳.小檗碱对小鼠和大鼠脑缺血的保护作用[J].中国药理学和毒理学杂 志,1995,9(2): 156
[4]Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease andits risk factors in the population of South China [J]. World J Gastroen2terol, 2007,13(47):6419-6424
[5]Fan JG,Zhu J,Li XJ,et al.Prevalence of and risk factors for fattyliver in a general population of Shanghai,China [J].J Hepatol,2005,43(3):508-514
[6]Enomoto N,Takei Y,Yamashina S,et al.Anti2inflammatory strategies in alcoholic steatohepatitis [J].J Gastroenterol Hepatol,2007,22(Suppl 1):S59-61
[7]Arteel G. Oxidants and antioxidants in alcohol2induced liver disease[J].Gastroenterology,2003,124(3):778-790
[8]Lieber CS. Alcoholic fatty liver:its pathogenesis and mechanism of progression to inflammation and fibrosis [J].Alcohol,2004,34(1):9-19
[9]Wu D,Cederbaum A.Oxidative stress mediated toxicity exerted by ethanol2inducible CYP2E1 [J].Toxicol App 1 Pharmacol,2005,207(2 Supp 1):70-76
[10]McClain C,Song Z,Barve S,et al.Recent advances in alcoholic liver disease IV Dysregulated cytokinemetabolism in alcoholic liver disease [J].Am J Physiol Gastrointest Liver Physiol,2004,287(3):G497-502
[11]Zhou Z,Wang L,Song Z,et al.A critical involvement of oxidative stress in acute alcohol2induced hepatic TNF2α p roduction [J].Am JPathol,2003,163(3):1137-1146
[12]Kharbanda KK,RogersDD,MailliardME,et al.Role of elevated S2 adenosyhomocysteine in rat hepatocyte apop tosis: Protection by betaine [J].Bochem Pharmacol,2005,70(12): 1883-1990
[1]冯志强,沈志祥,谭诗云.酒精性脂肪肝的发病机制研究进展[J].世界华人消化杂志,2002,10:3462348
[2]李秀清,国兰庭,李长林,等.自由基与丹参的临床应用概况[J].时诊国药研究,1997,8(6):565
[3]Baraona E,Lieber CS.Alcohol and lipids[J].Recent Dev Alcohol,1998,14:97-134.
[4]王雁翔.脂肪肝中药治疗进展[J].中医研究2004,17(1):61-64
[5]徐黎明.中药对酒精性肝损伤的实验研究进展[J].抗感染药学2004,1(3)108-109
[6]吴俊芳.小檗碱对小鼠和大鼠脑缺血的保护作用[J].中国药理学和毒理学杂志,1995,9(2):156-158
[7]阎明,孟繁立,贾晓青,等.酒精性脂肪肝血清游离脂肪酸谱的变化[J].中华消化杂志,2003,23(8):505-506
[8]CHITTURIS,FARRELLG,FROSTL,etal.Serumleptinin NASHcorrelates with hepaticsteatosis but notfibrosis:amanifes-tationoflipotoxicity[J].Hepatology,2002,36:403-409
[9]农兵,罗和生,梁增文,等.瘦素在实验性大鼠肝纤维化发生中的作用机制研究[J].华夏医学.2006,19(3):386-388
[10]ZWIRSKAKORCZALAK,DZIAMBORAP,WICZKOWSKIA,etal.Hepatocytes growth factor(HGF),leptin,neopterin serum concentration in patients with chronic hepatitis[J].PrzeglEpi-demiol,2001,55(Suppl3):164-169
[11]陈银华,雷陵,张茂林.神农肝脂宁对大鼠实验性脂肪肝的影响[J].中西医结合肝病杂志.2003,13(4):221-222
[1]范建高,朱军,李新建.等上海市成人脂肪肝患病率及其危险因素流行病学调查[J].中华肝脏病杂志,2005,13(2):87
[2]厉有名,陈卫星,虞朝辉,等.浙江省酒精性肝病流行病学调查概况[J].中华肝脏病杂志,2003,11(11):649
[3]施军平,邬菊英,潘红英,等.酒精性脂肪肝患者血浆ET、TNF-a水平变化及临床意义[J].浙江中医学院学报,2002,26(3):26
[4]张弘英,叶如美,朱水山,等.酒精性肝病38例临床分析[J].江西医学院学报,2005,45(3):130
[5]侯留法,陈宝玲,赵玉瑶,等.酒肝消脂冲剂治疗酒精性脂肪肝102例[J].中国中西医结合杂志,2003,23(6):413
[6]高学清.王正君消脂益肝汤治疗酒精性脂肪肝的临床观察[J].湖北中医杂志,2005,27(5):38
[7]张传平,张志红.酒精性脂肪肝的研究进展[J].实用中医药杂志,2001,17(11):22-23
[8]李华,张伟,曾斌芳.降脂护肝汤治疗酒精性脂肪肝63例[J].新疆医药,2001,19(3):21
[9]董子强.益肾洗肝化脂汤治疗酒精性脂肪肝40例临床研究[J].河南中医,2002,22(3)29-30
[10]董子强,赵勇军,史玉霞.益肾洗肝化脂汤对酒精性脂肪肝患者BUA、TBA的影响[J].国医论坛,2003.18(2):20-21
[11]王延,康秋华,王显刚.酒精性脂肪肝的中医药防治[J].山东中医药大学学报,2000,24 (3):240
[12]赵文霞,张慧.慢性病毒性肝炎合并脂肪肝的中医药临床研究进展[J].河南中医,2004,24(12):80
[13]肖文海,王乐园.安络化纤丸联合黄芪注射液治疗酒精性脂肪肝53例[J].中西医结合肝病杂志,2005,15(6):375
[14]康谊,陈瑞.扶肝理脾方治疗酒精性脂肪肝12例[J].中国中西医结合消化杂志,2006,14(6):342
[15]史海立,赵庆华.化肝降脂汤治疗酒精性脂肪肝(气郁痰湿型)的临床观察[J].中医药信息,2008,25(5):41
[16]沈国良,高雅文,王丽萍,钟建亮.化痰消脂益肝汤治疗酒精性脂肪肝124例[J].中国中医药信息杂志,2004,11(11):1000
[17]张慧.赵文霞教授治疗酒精性脂肪肝经验[J].河南中医,2005,25(8):17
[18]鞠庆,汤志顺.降脂汤治疗酒精性脂肪肝45例[J].实用中医杂志,1997,25(6):17
[19]黄怀文,王书军.健肝汤治疗酒精性脂肪肝50例[J].中西医结合肝病杂志,2001,11(2):110
[20]侯留法,杜建军,孙玉信,酒肝康汤治疗酒精性脂肪肝32例[J].河南中医,1997,17(4):225
[21]张诗军,陈泽雄,李俊标.清热祛湿通络法治疗酒精性脂肪肝疗效观察[J].中药材,2002,25(5):378
[22]于学美,张成博,韩 涛,赵益梅.论肝气虚在酒精性脂肪肝发病中的作用[J].山东中医药大学学报,2005,29(2):98-99
[23]余卓文,李杏儿,周丽仪.,消脂解酒方治疗酒精性脂肪肝58例疗效观察[J].新中医,2006,38(6):28-29
[24]隋炳运.益肝祛脂汤治疗酒精性脂肪肝78例疗效观察[J].中医中药,2006,16(3):271
[25]王生耀,王月君.茵陈蒿汤合柴胡疏肝散治疗酒精性脂肪肝46例[J].亚太传统医药,2007,5:54
[26]潘志坚,钟洋鑫.柴胡疏肝散治疗酒精性脂肪肝60例[J].实用中医药杂志,2001,17(11):22
[27]董子强,赵勇军,史玉霞.益肾洗肝化脂汤对酒精性脂肪肝患者BUA、TBA的影响[J].国医论坛,2003,18(2):20
[28]张明雪,藏佩林.酒精性脂肪肝的中医证治与微观化研究[J].中医函授通讯,1997,16 (6):16
[29]毕光安.酒精性脂肪肝证治体会[J].实用中医杂志,2004,20(10):587
[30]任泽久,龚清,陈悦.等疏肝健脾汤治疗酒精性脂肪肝疗效观察[J].湖北中医杂志,2004,26(5):20
[31]鞠丽君,鞠传兰,汪萌.祛脂护肝冲剂治疗酒精性脂肪肝的临床观察[J].中国中西医结合杂志,2002,22(8):629
[32]曾玲,江永苏.调肝降脂液治疗酒精性脂肪肝51例[J].四川中医,2004,22(3):64
[33]李方,陈强松.复方丹参养肝汤治疗酒精性脂肪肝45例[J].陕西中医,2007,28(9):1180
[34]刘三都.肝脂灵胶囊治疗酒精性脂肪肝50例[J].陕西中医,2006,26(9):1070
[35]杨梅,刘爱丽,魏敏.葛花决明饮治疗洒精性脂肪肝68例临床观察[J].新乡医学院学报,2005,22(4):336
[36]史海立,赵庆华,化肝降脂汤治疗酒精性脂肪肝(气郁痰湿型)的临床观察[J].中医药信息,2008,25(5):41
[37]刘彩莉,张雪梅.肝脂清联合甘利欣治疗酒精性脂肪肝的临床观察[J].光明中医,2007,22(12):81
[38]梁卫,徐华强,张丽玲,龚林,谢琼梅,王锦兰.解酒消脂汤治疗酒精性脂肪肝临床研究[J].时珍国医国药,2007,18(11):2817
[39]董子强.益肾洗肝化脂汤治疗酒精性脂肪肝40例临床研究[J].河南中医,2002,22(3):29
[40]蒋仁发,江永苏,邓家斌,黄文进,封浩德,姚安延.柴芩调肝液治疗酒精性脂肪肝的临床观察[J].现代医药卫生,2004,20(1):49
[41]贾静鹏,蒋森.枳葛益肝汤治疗酒精性脂肪肝102例临床观察[J].中医杂志,2003;44(10):750
[42]张明雪,藏佩林.酒精性脂肪肝的中医证治与微观化研究[J].中医函授通讯,1997,16(6):16
[43]王刚,姚毅,王海涛.垂葛酒肝汤配合硫普罗宁治疗酒精性脂肪肝36例[J].四川中医,2006,27(7):42
[44]康红钰,张银萍.降脂保肝丸治疗酒精性脂肪肝38例的疗效观察[J].医学论坛,2007,2:17
[45]李华,张伟,曾斌芳.降脂护肝汤治疗酒精性脂肪肝63例[J].新疆中医药,2001,19(3):22
[46]高学清,王正君.消脂益肝汤治疗酒精性脂肪肝的临床观察[J].湖北中医杂志,2005,27(5):38
[47]李彬,郝巧光.解酒肝康汤治疗酒精性脂肪肝临床疗效评价[J].光明中医,2007,22(9):62
[48]古赛,姜蓉.枸杞多糖防治大鼠酒精性脂肪肝的作用及机制研究[J].中国药房,2007,18(21):1606
[49]张禁,谭诗云,蒋琳,朱卫芳,程景辉.懈皮素对大鼠酒精性脂肪肝核转录因子表达的影响[J].世界华人消化杂志,2007,15(22):2399
[50]朱东,付淑艳,朱肖鸿,陈明涛,倪桂宝,刘勇林.芦荟煎剂对大鼠酒精性脂肪肝T细胞亚群的影响[J].中医药学刊,2006,24(10):1857
[51]陈芝芸,严茂祥,蔡丹莉,何蓓晖,陈华,刘庆牛.三七抗酒精性脂肪肝的实验研究[J].中华中医药杂志,2006,21(10):614
[52]徐中南,谢梅林,陆伦根,田心,朱路佳,薛洁,张克平,陈尉华,刘梅,茅益民,曾民德.甜菜碱对大鼠酒精性脂肪肝的影响[J].中华肝脏病杂志,2006,11(3):163
[53]朱肖鸿,朱强,叶蕾,等.枳子对大鼠酒精性脂肪肝的预防作用及机制[J].中西医结合肝病杂,2007,17(4):220
[54]YoshikawaM,Ywurakami T.Vede T,et al.Bioactive saponins and agtycosides.ⅣFourmethyh migrated 16,17-seco-dam marane triter2pene glycosides from Chinese,Hoveniae senmen seu fructus.Theseeds fruit of Hoveniae dulcis Thunb;abosotute stereostructures andinhibition activity on his tamine releasa of hovcnidulc iosidcs A1,A2,Bland B2.Chem Pham Bull,1996,44(9):1736
[55]贾青,张维东,王朝霞,张月英.柞蚕雄蛾液对酒精性脂肪肝小鼠保护作用的研究[J].现代中西医结合杂志,2007,16(22):3151
[56]李皴绯,孟祥伟.酒精性肝病的中西医治疗现状[J].吉林医学,2006,27(3):232
[57]夏玉涛,卫新革,陈颖伟,等.大黄素对肝纤维化大鼠血清透明质酸的影响[J].中西医结合肝病杂志,1999;9(4):27.
[58]陈在忠,王红.川芎嗪抗肝纤维化作用的实验研究[J].中西医结合杂志,1997;7(3):156.
[59]马安林,吴铁墉,董恩玉.中西医结合肝病杂志,2000;10(6):34.
[60]马力春,李福全,赵玉珍,等.西洋参茎叶皂甙对急性乙醇中毒大鼠肝损害的影响[J].佳木斯医学院学报,1992,15(2):18-19.
[6l]范建高,曾民德,钟岚,等.牛黄酸、金牡蛎对大鼠酒精性肝损伤的防治作用[J].中华肝脏杂志,1999,4(3):154-156.
[62]赖凌燕.丹参对实验性酒精肝损伤保护作用的初步研究[J].广西医科大学学报,1999,16(4):480-481.
[63]李宗友.人参对大鼠血浆中乙醉浓度的影响[J].国外医学中医中药分册,1994,16(2):40
[64]钟鸣,黄琳芸,余胜民,等.排钱草对大鼠实验性肝纤维化的影响[J].中西医结合肝病杂志,1999,9(4):22-24.
[65]杨牧祥,田元祥,姚树坤,等.解酒护肝饮对酒精性肝损伤大鼠血清和肝组织ALT、AST的影响[J].河北中医,2000,22(10):793-796.
[66]李育浩,邓响嘲,吴清和,等.五子衍宗丸对乙醇性肝损伤大鼠脂质代谢的影响[J].中国中药杂志,1994,19(5):300-302.
[67]李东良,郭红哲,于晓玲,等.柴寇冲剂对大鼠慢性酒精性肝损伤防护作用的实验研究[J].中国中医药科技,2000,7(3):141-142.
[68]蒙一纯,丁一霞,贲长恩,等.益气活血方对肝星状细胞(HSC)Ⅰ型胶原的表达影响的研究[J].中国中医药科技,2000,9(1):5-7.
[69]叶永安,田德禄,赵凤志,等.慢肝消对酒精性肝损伤大鼠肝脏病理学及组织化学变化的影响[J].北京中医药大学学报,1997,20(1):43-44.
[70]叶永安,田德禄,黄哲,等.“慢肝消”对大鼠酒精性肝损伤血清生化的影响[J].北京中医药大学学报,1999,22(6):31-33.
[71]赵丽云,丁霞,蒙一纯,等.调肝理脾方抗酒精性肝纤维化大鼠的免疫组化及图像分析研究[J].北京中医药大学学报,2000,23(2):25-27.
[72]于学美,韩涛,崔西泉,孙建翠.补益肝气方药对酒精性脂肪肝模型大鼠TNF-α含量的影响[J].泰山医学院学报,2007,11(28):841
[73]潘年松,黄勋,王毅,张立实.护肝灵对实验大鼠酒精性脂肪肝的影响与机制探讨[J].陕西中医2007,28(9):1265
[74]亓勇,赵学印.降脂保肝丸治疗酒精性脂肪肝的实验研究[J].中西医结合肝病杂志,2008,18(3):167
[75]邸琳,刘新宇,金向群,李海燕,常福红.酒肝清胶囊对实验性大鼠酒精性脂肪肝的治疗作用[J].中国实验方剂学杂志,2008,14(3):53
[76]李亚峰,姚树坤.中药脂肝宁对酒精加高脂饮食大鼠脂肪肝丙二醛、谷胱甘肽的影响[J].河北医科大学学报,2003;24(4):204
[77]田翠时,薄爱华,李仲平.护肝饮对饮酒大鼠肝细胞形态变化的影响[J].中西医结合肝脏杂志,2003;13(4):213
[78]许惠珍.三黄肝之宝对复合因素致大鼠脂肪肝的影响[J].湖北中医学院学报,2002; 4(1):25
[79]门奈丈之.小柴胡汤对酒精性脂肪肝的防护作用[J].国外医学·中医中药分册,1998,10(5):54
[80]杨晋翔编译.酒精性肝损害、脂肪肝与汉方[J].国外医学·中医中药分册,1998,16(6):6
[81]华海婴,张转建,付康,杨波,王曙炎,戈士文,叶启霞.清脂复肝颗粒防治大鼠酒精性脂肪肝的疗效及机制研究[J].中华中医药杂志,2008,23,(6):487
[82]朱本贵,李昌平,单连云,陈霞.舒肝颗粒对大鼠酒精性脂肪肝的疗效及其机制[J].现代中西医结合杂志,2006,15(19):2615
[83]孙小英.中西药治疗大鼠酒精性脂肪肝的疗效观察及病理分析[J].现代中西医结合杂志,2008,17(19):2941
[84]史亚祥.消脂活血饮联合西利宾胺治疗酒精性脂肪肝机理的实验研究[J].江苏中医药杂志,2007,6(39):62
[1]EnomotoN,TakeiY,Yamashina S,eta.l Anti-inflammatory strategies in alcoholic steatohepatitis[J].J Gastroenterol Hepato,l 2007,22(Suppl1):S59-61
[2]Arteel G.Oxidants and antioxidants in alcohol-induced liver disease[J].Gastroenterology,2003,124(3):778-790
[3]Lieber CS.Alcoholic fatty liver:its pathogenesis and mechanism of progression to inflammation and fibrosis[J].Alcoho,l 2004,34(1):9-19
[4]Wu D,Cederbaum A.Oxidative stress mediated toxicity exerted by ethanol-inducible CYP2E1[J].ToxicolAppl Pharmaco,l 2005,207(2 Suppl):70-76
[5]McClain C,SongZ,Barve S,eta.l Recentadvances in alcoholic liv-er disease Ⅳ.Dysregulated cytokinemetabolism in alcoholic liverdis-ease[J].Am J PhysiolGastrointestLiver Physio,l 2004,287(3):G497-502
[6]Zhou Z,Wang L,Song Z,et a.l A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-α production[J].Am J Patho,1 2003,163(3):1137-1146
[7]YinM,WheelerMD,KonoH,eta.l Essential role of tumornecrosis factor-αin alcohol-induced liver injury[J].Gastroenterology,2004,10(4):1329-1332
[8]KharbandaKK,RogersDD,MailliardME,eta.l Role ofelevated S-adenosyhomocysteine in rat hepatocyte apoptosis:Protection by beta-ine[J].Bochem Pharmaco,1 2005,70(12):1883-1990
[9]ZHAO CY,J[ANGL,L I ZJ,et al.Peroxisome proliferator activated receptor2gamma in pathogenesis of experimental fatty liver disease[J].J Gasteroenterol,2004,10:1329-1332
[10]MACSWEEN RN,BURT AD.Histologic spect rum of al- coholic liver disease [J].Semin Liver Dis,1986,6:221-232
[11]FISHER M,YOU M,MATSUMOT O,et al.Peroxisome proliferator activated receptor alpha agonist treatment reverses PPAR alpha dysfunction and abnormali-ties in hepatic lipid metabolism in ethanol-fed mice[J].J Biol Chem,2003,278:27997-28004
[12]BYKOV I,JARVELAINEN H,L INDROS K L-Car-tinite alleviates alcohol induced liver damage in rats:Role of tumor necrosis factor-alpha[J].Alcohol Alcoholism,2003,38:400- 406
[13]GALL I AJ,PINAIRE M,FISCHER R,et al.The transcriptional and DNA activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol-induced fatty liver[J].J Biol Chem,2001,276:68-75
[14]王海霞,贾柳萍,陈其李,等.酒精性脂肪肝患者血脂水平与肝组织病理改变相关性的实验研究[J].国际消化病杂志,2006,26:211-212
[15]池晓玲,陈培琼,萧焕明,等.肝病治疗仪治疗酒精性脂肪肝82例临床观察[J].中国中医药信息杂志,2005,12:73
[16]姚希贤,南月敏,王莹,等.高脂高糖、饮酒建立家兔脂肪肝模型及超声量化诊断[J].世界华人消化杂志,2006,24:1484-1485
[17]赵虹,刘彬祥,张利中,等.CT定量诊断脂肪肝的实验室研究[J].中华放射学杂志,1997,31:836-838
[18]曹茜,刘连祥,吴晶,等.脂肪肝的MR诊断[J].实用放射学杂志,1997,13:6272628
[19]李玉华,姚华,徐菲莉,等.酒精性脂肪肝与非酒精性脂肪肝患者生化指标的对比分析[J].新疆医科大学学报,2005,28:392-393
[20]Sorbi D,Boynton J,lindor KD.The ratio of aspartate aminotransferase to alanine aminotransferase:potential value in differentiating nonalcoholic steatohepatitis from alocholic liver disease.AmJ Gastroenterol,1999,94:1018-1022
[21]司维柯.血清GG物测定现状与临床诊断价值[J].国外医学临床生物化学与检验学分册,1991,12:254-556
[22]张建华,杨文东,刘民.长期大量饮酒者肝功能和血脂检测指标变化的临床分析[J].实用诊断与治疗杂志,2006,20:258
[23]范建高.酒精性与非酒精性脂肪性肝病[J].中华肝脏病杂志,2003,11:692
[24]MERKEL C,MARCHESINI G,FABBRI A,et al.The course of galactosec elimination capacity in patients with alcoholic cirrhosis:possible use as a surrogate marker for death[J].Hepatology,1996,24:820-823
[25]LIBER CS,WEISS DG,GROSZMANN R,et al.Veterans Affiairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease:effects on drinking behavior by nurse/physician teams[J].Alcohol Clin Exp Res,2003,27:757- 1764
[26]MENDENHALL CL,ROSSSELLE GA,GARTSIDE P,et al.Relationship of protein calorie malnutrition to alco-holic liver disease:a reexamination of data from two Vet-erans Administration Cooperative Studies[J].Alcoholic Clin Exp Res,1995,19:635-641
[27]HIRSCH S,BUNOUT D,MAZA P,et al.Controlled trial on nutrition supplementation in outpatients with symp-tomatic alcoholic cirrhosis[J].JPEN J Parenter Enteral Nurr,1993,17:119-124
[28]KEARNS PJ,YOUNG H,GARCIA G,et al.Accelerated improvement of alcoholic liver disease with enteral nutri- tion[J].Gastroenterology,1992,102:200-205
[29] LAMBERT JC,ZHOU Z,WANG L,et al.Prevention of intestinal structural integrity by zincid independent of metallothionein in alcohol-intoxicated mice [J].AM J Pathol,2004,164:1959- 1966
[30] MATHURIN P,MENDENHALL CL,CARITHERS RL,etal. Corticosteroids improve shortterm survival in patients with severe alcoholic hepatitis(AH) individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH[J].J Hepatol,2002,36:480-487
[31] AKRIVIADIS E,BOTLA R,BRIGGS W,et al.Pentoxi-fylline improves short-term survival in severe acute alco-holic hepatitis: a double-blind, placebo-controlled trial [J]. Gastroenterology,2000,119:1637-1648
[32] TILG H,JALAN R,KASER A,et al.Anti-tumor necro-sis factor-alpha monoelonal antibody therapy in severe al-coholic hepatitis[J].J Hepatol, 2003,38:419-425
[33] MENON KV,STADHEIM L,KAMATH PS,et al.A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis[J]. Am J Gaxtroen-terol, 2004,99:255-260.
[34] MORGAN TR,NEMCHAUSKY N,SCHIFF E,et al Colchicine does not prolong life in patients with advanced alcoholic cirrhpsis: results of a prospective,ran-domized,placebocontrolled, multicenter VA trial[J] Gastroenterology ,2002,122:641
[35] CORTEZ-PINTOH,ALEXANDRINO P,CAMILO ME,et al.Lack of effect of colchicines in alcoholic cirrhosis: final results of a double blind randomized trial[J].Eur J Gastro-enterol Hepatol ,2002,14:377-381
[36] RAMBALDI A,IAQUINTO G,GLUUD,C,et al.Anaboli-ucandrogenic steroids for alcoholic liver disease: a ochrane review[J].Am J Gastroenterol,2002,97:1674-1681
[37] PARES A,PLANAS R,TORRES M,et al.Effects of si-lymarin in alcoholic patients with cirrhosis of the liver:results of a controlled, double-blind, randomized and multicenter trial[J]. J Hepatol, 1998,28:615-621
[38] LEE TD,SADDA MR,MENDLER MH,et al.Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis[J].Alcohol Clin Exp Res,2004,28:173-181
[39] SANCHEZ-GONGORAQ E,RUIZ F, MINGORANCE J,et al. Interaction of liver methionine adenosyltransferase with hydroxyl radical[J]. FASEB J, 1997,11:1013-1019
[40]SONG Z,MCCLAIN CJ,CHEN T,et al.S-adenosylmethionine protects against acetaminophen-induced hepatotoxitcity in mice[J].Pharmacology,2004,71:199-208
[41]MCCLAIN CJ,HILL DB,SONG Z,et al.S-adenosylmethionine,cytokines,and alcoholic liver disease[J].Alcohol,2002,27:185-192
[42]MATO JM,CAMARA J,FERNANDEZ DP,et al.S-adenosylmethionine in alcoholic liver cirrhosis:a randomized,placebo-controlled,double-blind,multicenter clinical trial[J].J Hepatol,1999,30:1081-1089
[43]MCCLAIN CJ,HILL D,KUGELMAS M,et al.Nutrition and liver disease:in Rm B:Present Knowledge in Nutrition[J].Washington,International Life Sciences Institute,2001,483-496
[44]HILL DB,DEVALARAJA R,JOSHI-BRAVE S,et al.Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells,in vivo[J].Clin Biochem,1999,32:563-570
[45]MEZEY E,POTTRER JJ,RENNIE-TANKERSLEY L,et al.A randomized placebo controlled trial of vitamin E for alcoholic hepatitis[J].J Hepatol,2004,40:40-46
[46]BJELAKOVIC G,NIKOLOVA D,SIMONETTI RG,et al.Antioxidant supplements for prevention of gastrointestinal cancers:a systematic review and meta-analysis [J].Lancet,2004,364:1219-1228
[47]MILLER ER,PASTOR-BARRIUSO R,DALAL D,et al.Meta-analysis:high-dosage vitamin E supplementation may increase all-cause mortality[J].Ann Inter Med,2005,142:37-46
[48]PENA LR,HILL DB,MCCLAIN CJ.Treatment with glutathione precursor decreases cytokine activity[J].JPEN J Parenter Enteral Nutr,1999,23:1-6
[49]HALSTED CH,VILLLANUEVA JA,DEVLIN AM,et al.Metabolic interactions of alcohol and folate[J].J Nutr,2002,132(suppl):1367S-2372S
[50]JI C,KAPLOWIZ N.Betaine decreases hyerhomocysteinemia,endoplasmic reticulum stress,and liver injury in alcohol-fed mice[J].Gastroenterology,2003,124:1488-1499
[51]纪宝华.非药物治疗对高血压、肥胖、糖尿病和脂质代谢异常的重要性-中华内科杂志,1998,37:293
[52]吴悦陶,王觉生,陈干仁-体育运动对轻度高血压病患者血胰岛素的影响·中华内科杂志,1998,37:298
[2]厉有名,陈卫星,虞朝辉,等.浙江省酒精性肝病流行病学调查慨况[J].中华肝脏病杂志,2003,11(11):649
[3]施军平,邬菊英,潘红英,等.酒精性脂肪肝患者血浆ET、TNF-a水平变化及临床意义[J].浙江中医学院学报,2002,26(3):26
[4]范建高.酒精性与非酒精性脂肪性肝病[J].中华肝脏病杂志,2003.11(11):692
[5]M cCullough AJ,O,Connor JF.Alcoholic liver disease:proposed recommendations for the American Collrge of Gastroenterology.AM J Gastroenol 1998;93:2022-2036
[6]王炳元,傅宝玉教授.酒精性肝病的诊断与治疗[J].中华肝脏病杂,2001.9(5):313
[7]李俊峰,杨冬华.非酒精性脂肪性肝病的药物治疗[J].临床荟萃,2004,19(22):1304-1306
[8]Chawla Rk,Hussaim.S,Watson WH,et al.Effect of Ethanol Consumption on Metabolism of SAMe in Rat Liver,Druu Invest,1992,4(Suppl4):S41
[9]河福全,贲长恩,王德福等.小柴胡汤对大鼠酒精性肝病防护作用的组化和生化研究[J].北京中医药大学学报,1997,20(1):45-47
[10]张茂信.搜剔通络为主治疗早期肝硬变腹水24例[J].湖北中医杂志.1996,18(3):42
[11]常惟智.中医药治疗脂肪肝研究进展概况[J].中医药学报.2005,33(3):64-66
[12]孔祥廉.脂肪肝的中医治疗[M].中国中医药出版社.85页
[1]叶永安.酒精性肝病中医认识初探[J].中国医药学报,1997:12(5):8-10
[2]金容炫,张浩,田德禄.田德禄教授治疗酒精性肝病的临床验[J].中国中医基础医学杂志,2003;9(8):66-67
[3]欧琴.酒精性肝病中医药研究进展[J].河北中医,2002;24(11):870-871
[4]任延明.酒精性肝病的中医病机浅探[J].青海医学院学报,2004;25(2):140-141
[5]华一利,陈建伟,吴惫平,等.明党参降血脂作用的实脸研究[J],南京中医学院学报,1994.10(4):31
[6]吴惫平,陶学勤,陈建伟,等.明党参不同提取物对大鼠肝匀浆上清液生成脂质过权化物的影响[J].南京中医学院学报,1993.9(1):26
[7]吴惫平,华一利,席蓓润,等.明党参在大鼠高胆固醉血症中扰载化作用[J].南京中医学院学报,1994.10(4):33
[8]李素婷,齐洁敏,杨鹤梅,等.柴胡总提物对大鼠酒精性肝损伤的保护作用[J].承德医学院学报,2007,24(1):9-10
[9]李芳,李建北,张东明.柴胡的药理研究进展[J].时珍国医国药,2004;15(2):120-121.
[10]邵淑丽.柴胡、姜黄对小白鼠实验性高脂血症的预防作用[J].中医药学报,2002;30(4):59-59。
[11]蒋天佑.白术的研究进展[J].中医药研究,2004,6(5):59
[12]邹祖绳.中医研究员资料汇刊(第一辑)[J],上海科学技术出版社,1996,13(5):26
[13]毛俊浩,吕志良,曾群力,等.白术糖对小鼠淋巴细胞功能的调节[J].免疫学杂志,1996,12(4):233
[14]陈岳祥,李石,范列英,等.丹参单体I H7643抗肝纤维化作用的实验研究[J].中华医学杂志,1998,76(8):636
[15]吕冰,陈红旗,赵勇刚,等.丹参治疗重型颅脑损伤的临床应用[J].医师进修杂志,1999,22(1):19
[16]戚心广,稻田丰.丹参、赤芍对实验性肝损伤肝细胞保护作用的机理研究[J].中国中西医结合杂志,1991,11(2):102
[17]孙克勤,李素芝,刘厚东,等.丹参对高原大鼠缺血再灌注损伤的保护作用[J].中国民间医学杂志,2005,17(1):10-11
[18]王树立,李永德,赵勤,等.山碴、黄茂及刺五加对豚鼠胆固醇代谢的影响[J].中国中西医结合杂志,2007,7(8):483
[19]翁维良.降血脂中草药研究进展[J].天津中医,2006,3(1):34
[20]王伟,陈文为.从抗氧化反应探讨“药食同源”的含义[J].中西医结合杂志,2004,11(3):159
[21]崔香玉.决明子乙醇提取物对大鼠急性肝损伤的保护作用[J].延边大学医学学报,2006,29(4):244-246
[22]林冬静,金政.决明子提取物对急性肝损伤保护作用的实验研究[J].时珍国医国药,2006,17(2):214-215
[23]任秀兰.重用赤芍治疗肝病重度黄疸[J].山西中医,2000;(5):10
[24]胡梅雪.活血化瘀法治疗肝纤维化[J].中医药学报,1998;(2):13
[25]黄孔威,傅乃武.赤芍对免疫功能的影响[J].药学通报,1982;17(10):54.
[26]戚心广.丹参、赤芍对实验性肝损伤肝细胞保护作用的机理研究[J].中西医结合杂志,1991:11(2):102
[27]张希恩,王利华.大黄保肝利胆作用的药理与临床[J].中医药研,1995;(4):56
[28]胡林华,等.生大黄的实验研究及肝性昏迷的临床观察[J].江苏医药,1994;20(6):304
[29]焦东海,等.精制大黄片治疗急性病毒性肝炎的研究[J].中医杂志,1990;31(9): 35
[30]YUANGohua,WEIJin,ZHOUJingguo,etal.Aoptosis of Human Hepatoma Cells Induced by Gynstemma Pentaphyllum Makino[J].The Chinese German Journal of Clinical On cology,2006,5(3):173-177
[31]陈几香,张建国,张莉,等绞股蓝总皂苷保肝作用实验研究[J]中国药业,2007,16(13):7-8
[32]ChenJC,TsaiCC,ChenLD,etal.Am Therapeutic effect of gypenoside on chronic liver injury and fibrosis induced by CC14 inrats[J]JchinMed,2000,28(2):175-185
[33]何冬宁,等.牡蛎提取营养液对大剂量CC14致小鼠急性肝损伤的保护作用[J].中国公共卫生学报,1997,16(3):152
[34]范建高,等.牛磺酸、金牡蛎对大鼠酒精性肝损伤的防治作用[J].中华肝脏病杂志,1999,4(3):154)
[35]罗琼,阎俟,李瑾玮,等.枸杞及其多糖对家免血脂的影响[J]营养学报,1997,19(2):415-418
[36]衣艳君.枸杞降血脂作用的实验研究[J].首都师范大学学报(自然科学版),2000,21(4):68-70
[37]闫秀英,许志华,韩丽莎,等.枸杞子对四氯化碳致大鼠肝脂类过氧化作用的抑制[J].包头医学院学报,1998;14(1):7-8
[38]边纶,沈新生,王燕蓉,等.枸杞多糖对四氯化碳所致小鼠肝损伤修复作用的形态学研究[J].宁夏医学杂志,1996;18(4):196-198
[39]白秀珍,王文忠,赵东.首乌、黄芪、天麻对血清羟脯氨酸含量影响的实验研究[J].锦州医学院学报,1994,15(1):27,80
[40]Wijaya-E,Wu-Z-M,Ng-F.Effect of Slimax',a Chinese herbal mixture,on obesity[J].INT-J-PHARMACOGN,1995,33(1):41-46
[41]李丽春,吴晓东,田维熙.何首乌提取物对脂肪酸合酶的抑制作用[J].中国生物化学与分子生物学报,2003,19(3):297-304
[42]刘成基,张清华,林军.炮制何首乌对小鼠实验性肝损伤后肝脂代谢的影响[J].中国中药杂志,1992,17(10):595-596
[43]金国琴,赵伟康.首乌制剂对老年大鼠胸腺、肝脏蛋白质和核酸含量的影响[J].中草药,1994,25(11):590-491,589
[44]HanYO,HanMJ,ParkSH,etal.Protective effeets ofkakkalide from Flos Puerariae on ethano-induced lethality and hepatic injury are dependent on its biotransformation by human intestinal microflora[J].J Pharmacol Sci,2003,93(3):331-336
[45]Ni iho Y,YamaZaki T,Nakajima Y,etal.Pharmacological studies on Puerariae Flos.I.The effeets of Puerariae Flos on alcoholic metabolism and spontaneous movement in mice[J].Yakugaku Zasshi,1989,109(6):424
[46]田代华.实用中药辞典(下卷)[M].北京:人民卫生出版社,2002,1897.
[47]芦洁,李文哲,倪亚明.中药水提取物对乙醇脱氢酶活性影响的初步研究[J].同济大学学报医学版,2002,23(1):23
[1]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南(2006年2月修订)[J].现代消化及介入诊疗,2007,(4):268-270
[2]郑筱萸.中药新药临床研究指导原则[M].中国医药科技出版社,2002:361-383
[3]吴俊芳.小檗碱对小鼠和大鼠脑缺血的保护作用[J].中国药理学和毒理学杂 志,1995,9(2): 156
[4]Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease andits risk factors in the population of South China [J]. World J Gastroen2terol, 2007,13(47):6419-6424
[5]Fan JG,Zhu J,Li XJ,et al.Prevalence of and risk factors for fattyliver in a general population of Shanghai,China [J].J Hepatol,2005,43(3):508-514
[6]Enomoto N,Takei Y,Yamashina S,et al.Anti2inflammatory strategies in alcoholic steatohepatitis [J].J Gastroenterol Hepatol,2007,22(Suppl 1):S59-61
[7]Arteel G. Oxidants and antioxidants in alcohol2induced liver disease[J].Gastroenterology,2003,124(3):778-790
[8]Lieber CS. Alcoholic fatty liver:its pathogenesis and mechanism of progression to inflammation and fibrosis [J].Alcohol,2004,34(1):9-19
[9]Wu D,Cederbaum A.Oxidative stress mediated toxicity exerted by ethanol2inducible CYP2E1 [J].Toxicol App 1 Pharmacol,2005,207(2 Supp 1):70-76
[10]McClain C,Song Z,Barve S,et al.Recent advances in alcoholic liver disease IV Dysregulated cytokinemetabolism in alcoholic liver disease [J].Am J Physiol Gastrointest Liver Physiol,2004,287(3):G497-502
[11]Zhou Z,Wang L,Song Z,et al.A critical involvement of oxidative stress in acute alcohol2induced hepatic TNF2α p roduction [J].Am JPathol,2003,163(3):1137-1146
[12]Kharbanda KK,RogersDD,MailliardME,et al.Role of elevated S2 adenosyhomocysteine in rat hepatocyte apop tosis: Protection by betaine [J].Bochem Pharmacol,2005,70(12): 1883-1990
[1]冯志强,沈志祥,谭诗云.酒精性脂肪肝的发病机制研究进展[J].世界华人消化杂志,2002,10:3462348
[2]李秀清,国兰庭,李长林,等.自由基与丹参的临床应用概况[J].时诊国药研究,1997,8(6):565
[3]Baraona E,Lieber CS.Alcohol and lipids[J].Recent Dev Alcohol,1998,14:97-134.
[4]王雁翔.脂肪肝中药治疗进展[J].中医研究2004,17(1):61-64
[5]徐黎明.中药对酒精性肝损伤的实验研究进展[J].抗感染药学2004,1(3)108-109
[6]吴俊芳.小檗碱对小鼠和大鼠脑缺血的保护作用[J].中国药理学和毒理学杂志,1995,9(2):156-158
[7]阎明,孟繁立,贾晓青,等.酒精性脂肪肝血清游离脂肪酸谱的变化[J].中华消化杂志,2003,23(8):505-506
[8]CHITTURIS,FARRELLG,FROSTL,etal.Serumleptinin NASHcorrelates with hepaticsteatosis but notfibrosis:amanifes-tationoflipotoxicity[J].Hepatology,2002,36:403-409
[9]农兵,罗和生,梁增文,等.瘦素在实验性大鼠肝纤维化发生中的作用机制研究[J].华夏医学.2006,19(3):386-388
[10]ZWIRSKAKORCZALAK,DZIAMBORAP,WICZKOWSKIA,etal.Hepatocytes growth factor(HGF),leptin,neopterin serum concentration in patients with chronic hepatitis[J].PrzeglEpi-demiol,2001,55(Suppl3):164-169
[11]陈银华,雷陵,张茂林.神农肝脂宁对大鼠实验性脂肪肝的影响[J].中西医结合肝病杂志.2003,13(4):221-222
[1]范建高,朱军,李新建.等上海市成人脂肪肝患病率及其危险因素流行病学调查[J].中华肝脏病杂志,2005,13(2):87
[2]厉有名,陈卫星,虞朝辉,等.浙江省酒精性肝病流行病学调查概况[J].中华肝脏病杂志,2003,11(11):649
[3]施军平,邬菊英,潘红英,等.酒精性脂肪肝患者血浆ET、TNF-a水平变化及临床意义[J].浙江中医学院学报,2002,26(3):26
[4]张弘英,叶如美,朱水山,等.酒精性肝病38例临床分析[J].江西医学院学报,2005,45(3):130
[5]侯留法,陈宝玲,赵玉瑶,等.酒肝消脂冲剂治疗酒精性脂肪肝102例[J].中国中西医结合杂志,2003,23(6):413
[6]高学清.王正君消脂益肝汤治疗酒精性脂肪肝的临床观察[J].湖北中医杂志,2005,27(5):38
[7]张传平,张志红.酒精性脂肪肝的研究进展[J].实用中医药杂志,2001,17(11):22-23
[8]李华,张伟,曾斌芳.降脂护肝汤治疗酒精性脂肪肝63例[J].新疆医药,2001,19(3):21
[9]董子强.益肾洗肝化脂汤治疗酒精性脂肪肝40例临床研究[J].河南中医,2002,22(3)29-30
[10]董子强,赵勇军,史玉霞.益肾洗肝化脂汤对酒精性脂肪肝患者BUA、TBA的影响[J].国医论坛,2003.18(2):20-21
[11]王延,康秋华,王显刚.酒精性脂肪肝的中医药防治[J].山东中医药大学学报,2000,24 (3):240
[12]赵文霞,张慧.慢性病毒性肝炎合并脂肪肝的中医药临床研究进展[J].河南中医,2004,24(12):80
[13]肖文海,王乐园.安络化纤丸联合黄芪注射液治疗酒精性脂肪肝53例[J].中西医结合肝病杂志,2005,15(6):375
[14]康谊,陈瑞.扶肝理脾方治疗酒精性脂肪肝12例[J].中国中西医结合消化杂志,2006,14(6):342
[15]史海立,赵庆华.化肝降脂汤治疗酒精性脂肪肝(气郁痰湿型)的临床观察[J].中医药信息,2008,25(5):41
[16]沈国良,高雅文,王丽萍,钟建亮.化痰消脂益肝汤治疗酒精性脂肪肝124例[J].中国中医药信息杂志,2004,11(11):1000
[17]张慧.赵文霞教授治疗酒精性脂肪肝经验[J].河南中医,2005,25(8):17
[18]鞠庆,汤志顺.降脂汤治疗酒精性脂肪肝45例[J].实用中医杂志,1997,25(6):17
[19]黄怀文,王书军.健肝汤治疗酒精性脂肪肝50例[J].中西医结合肝病杂志,2001,11(2):110
[20]侯留法,杜建军,孙玉信,酒肝康汤治疗酒精性脂肪肝32例[J].河南中医,1997,17(4):225
[21]张诗军,陈泽雄,李俊标.清热祛湿通络法治疗酒精性脂肪肝疗效观察[J].中药材,2002,25(5):378
[22]于学美,张成博,韩 涛,赵益梅.论肝气虚在酒精性脂肪肝发病中的作用[J].山东中医药大学学报,2005,29(2):98-99
[23]余卓文,李杏儿,周丽仪.,消脂解酒方治疗酒精性脂肪肝58例疗效观察[J].新中医,2006,38(6):28-29
[24]隋炳运.益肝祛脂汤治疗酒精性脂肪肝78例疗效观察[J].中医中药,2006,16(3):271
[25]王生耀,王月君.茵陈蒿汤合柴胡疏肝散治疗酒精性脂肪肝46例[J].亚太传统医药,2007,5:54
[26]潘志坚,钟洋鑫.柴胡疏肝散治疗酒精性脂肪肝60例[J].实用中医药杂志,2001,17(11):22
[27]董子强,赵勇军,史玉霞.益肾洗肝化脂汤对酒精性脂肪肝患者BUA、TBA的影响[J].国医论坛,2003,18(2):20
[28]张明雪,藏佩林.酒精性脂肪肝的中医证治与微观化研究[J].中医函授通讯,1997,16 (6):16
[29]毕光安.酒精性脂肪肝证治体会[J].实用中医杂志,2004,20(10):587
[30]任泽久,龚清,陈悦.等疏肝健脾汤治疗酒精性脂肪肝疗效观察[J].湖北中医杂志,2004,26(5):20
[31]鞠丽君,鞠传兰,汪萌.祛脂护肝冲剂治疗酒精性脂肪肝的临床观察[J].中国中西医结合杂志,2002,22(8):629
[32]曾玲,江永苏.调肝降脂液治疗酒精性脂肪肝51例[J].四川中医,2004,22(3):64
[33]李方,陈强松.复方丹参养肝汤治疗酒精性脂肪肝45例[J].陕西中医,2007,28(9):1180
[34]刘三都.肝脂灵胶囊治疗酒精性脂肪肝50例[J].陕西中医,2006,26(9):1070
[35]杨梅,刘爱丽,魏敏.葛花决明饮治疗洒精性脂肪肝68例临床观察[J].新乡医学院学报,2005,22(4):336
[36]史海立,赵庆华,化肝降脂汤治疗酒精性脂肪肝(气郁痰湿型)的临床观察[J].中医药信息,2008,25(5):41
[37]刘彩莉,张雪梅.肝脂清联合甘利欣治疗酒精性脂肪肝的临床观察[J].光明中医,2007,22(12):81
[38]梁卫,徐华强,张丽玲,龚林,谢琼梅,王锦兰.解酒消脂汤治疗酒精性脂肪肝临床研究[J].时珍国医国药,2007,18(11):2817
[39]董子强.益肾洗肝化脂汤治疗酒精性脂肪肝40例临床研究[J].河南中医,2002,22(3):29
[40]蒋仁发,江永苏,邓家斌,黄文进,封浩德,姚安延.柴芩调肝液治疗酒精性脂肪肝的临床观察[J].现代医药卫生,2004,20(1):49
[41]贾静鹏,蒋森.枳葛益肝汤治疗酒精性脂肪肝102例临床观察[J].中医杂志,2003;44(10):750
[42]张明雪,藏佩林.酒精性脂肪肝的中医证治与微观化研究[J].中医函授通讯,1997,16(6):16
[43]王刚,姚毅,王海涛.垂葛酒肝汤配合硫普罗宁治疗酒精性脂肪肝36例[J].四川中医,2006,27(7):42
[44]康红钰,张银萍.降脂保肝丸治疗酒精性脂肪肝38例的疗效观察[J].医学论坛,2007,2:17
[45]李华,张伟,曾斌芳.降脂护肝汤治疗酒精性脂肪肝63例[J].新疆中医药,2001,19(3):22
[46]高学清,王正君.消脂益肝汤治疗酒精性脂肪肝的临床观察[J].湖北中医杂志,2005,27(5):38
[47]李彬,郝巧光.解酒肝康汤治疗酒精性脂肪肝临床疗效评价[J].光明中医,2007,22(9):62
[48]古赛,姜蓉.枸杞多糖防治大鼠酒精性脂肪肝的作用及机制研究[J].中国药房,2007,18(21):1606
[49]张禁,谭诗云,蒋琳,朱卫芳,程景辉.懈皮素对大鼠酒精性脂肪肝核转录因子表达的影响[J].世界华人消化杂志,2007,15(22):2399
[50]朱东,付淑艳,朱肖鸿,陈明涛,倪桂宝,刘勇林.芦荟煎剂对大鼠酒精性脂肪肝T细胞亚群的影响[J].中医药学刊,2006,24(10):1857
[51]陈芝芸,严茂祥,蔡丹莉,何蓓晖,陈华,刘庆牛.三七抗酒精性脂肪肝的实验研究[J].中华中医药杂志,2006,21(10):614
[52]徐中南,谢梅林,陆伦根,田心,朱路佳,薛洁,张克平,陈尉华,刘梅,茅益民,曾民德.甜菜碱对大鼠酒精性脂肪肝的影响[J].中华肝脏病杂志,2006,11(3):163
[53]朱肖鸿,朱强,叶蕾,等.枳子对大鼠酒精性脂肪肝的预防作用及机制[J].中西医结合肝病杂,2007,17(4):220
[54]YoshikawaM,Ywurakami T.Vede T,et al.Bioactive saponins and agtycosides.ⅣFourmethyh migrated 16,17-seco-dam marane triter2pene glycosides from Chinese,Hoveniae senmen seu fructus.Theseeds fruit of Hoveniae dulcis Thunb;abosotute stereostructures andinhibition activity on his tamine releasa of hovcnidulc iosidcs A1,A2,Bland B2.Chem Pham Bull,1996,44(9):1736
[55]贾青,张维东,王朝霞,张月英.柞蚕雄蛾液对酒精性脂肪肝小鼠保护作用的研究[J].现代中西医结合杂志,2007,16(22):3151
[56]李皴绯,孟祥伟.酒精性肝病的中西医治疗现状[J].吉林医学,2006,27(3):232
[57]夏玉涛,卫新革,陈颖伟,等.大黄素对肝纤维化大鼠血清透明质酸的影响[J].中西医结合肝病杂志,1999;9(4):27.
[58]陈在忠,王红.川芎嗪抗肝纤维化作用的实验研究[J].中西医结合杂志,1997;7(3):156.
[59]马安林,吴铁墉,董恩玉.中西医结合肝病杂志,2000;10(6):34.
[60]马力春,李福全,赵玉珍,等.西洋参茎叶皂甙对急性乙醇中毒大鼠肝损害的影响[J].佳木斯医学院学报,1992,15(2):18-19.
[6l]范建高,曾民德,钟岚,等.牛黄酸、金牡蛎对大鼠酒精性肝损伤的防治作用[J].中华肝脏杂志,1999,4(3):154-156.
[62]赖凌燕.丹参对实验性酒精肝损伤保护作用的初步研究[J].广西医科大学学报,1999,16(4):480-481.
[63]李宗友.人参对大鼠血浆中乙醉浓度的影响[J].国外医学中医中药分册,1994,16(2):40
[64]钟鸣,黄琳芸,余胜民,等.排钱草对大鼠实验性肝纤维化的影响[J].中西医结合肝病杂志,1999,9(4):22-24.
[65]杨牧祥,田元祥,姚树坤,等.解酒护肝饮对酒精性肝损伤大鼠血清和肝组织ALT、AST的影响[J].河北中医,2000,22(10):793-796.
[66]李育浩,邓响嘲,吴清和,等.五子衍宗丸对乙醇性肝损伤大鼠脂质代谢的影响[J].中国中药杂志,1994,19(5):300-302.
[67]李东良,郭红哲,于晓玲,等.柴寇冲剂对大鼠慢性酒精性肝损伤防护作用的实验研究[J].中国中医药科技,2000,7(3):141-142.
[68]蒙一纯,丁一霞,贲长恩,等.益气活血方对肝星状细胞(HSC)Ⅰ型胶原的表达影响的研究[J].中国中医药科技,2000,9(1):5-7.
[69]叶永安,田德禄,赵凤志,等.慢肝消对酒精性肝损伤大鼠肝脏病理学及组织化学变化的影响[J].北京中医药大学学报,1997,20(1):43-44.
[70]叶永安,田德禄,黄哲,等.“慢肝消”对大鼠酒精性肝损伤血清生化的影响[J].北京中医药大学学报,1999,22(6):31-33.
[71]赵丽云,丁霞,蒙一纯,等.调肝理脾方抗酒精性肝纤维化大鼠的免疫组化及图像分析研究[J].北京中医药大学学报,2000,23(2):25-27.
[72]于学美,韩涛,崔西泉,孙建翠.补益肝气方药对酒精性脂肪肝模型大鼠TNF-α含量的影响[J].泰山医学院学报,2007,11(28):841
[73]潘年松,黄勋,王毅,张立实.护肝灵对实验大鼠酒精性脂肪肝的影响与机制探讨[J].陕西中医2007,28(9):1265
[74]亓勇,赵学印.降脂保肝丸治疗酒精性脂肪肝的实验研究[J].中西医结合肝病杂志,2008,18(3):167
[75]邸琳,刘新宇,金向群,李海燕,常福红.酒肝清胶囊对实验性大鼠酒精性脂肪肝的治疗作用[J].中国实验方剂学杂志,2008,14(3):53
[76]李亚峰,姚树坤.中药脂肝宁对酒精加高脂饮食大鼠脂肪肝丙二醛、谷胱甘肽的影响[J].河北医科大学学报,2003;24(4):204
[77]田翠时,薄爱华,李仲平.护肝饮对饮酒大鼠肝细胞形态变化的影响[J].中西医结合肝脏杂志,2003;13(4):213
[78]许惠珍.三黄肝之宝对复合因素致大鼠脂肪肝的影响[J].湖北中医学院学报,2002; 4(1):25
[79]门奈丈之.小柴胡汤对酒精性脂肪肝的防护作用[J].国外医学·中医中药分册,1998,10(5):54
[80]杨晋翔编译.酒精性肝损害、脂肪肝与汉方[J].国外医学·中医中药分册,1998,16(6):6
[81]华海婴,张转建,付康,杨波,王曙炎,戈士文,叶启霞.清脂复肝颗粒防治大鼠酒精性脂肪肝的疗效及机制研究[J].中华中医药杂志,2008,23,(6):487
[82]朱本贵,李昌平,单连云,陈霞.舒肝颗粒对大鼠酒精性脂肪肝的疗效及其机制[J].现代中西医结合杂志,2006,15(19):2615
[83]孙小英.中西药治疗大鼠酒精性脂肪肝的疗效观察及病理分析[J].现代中西医结合杂志,2008,17(19):2941
[84]史亚祥.消脂活血饮联合西利宾胺治疗酒精性脂肪肝机理的实验研究[J].江苏中医药杂志,2007,6(39):62
[1]EnomotoN,TakeiY,Yamashina S,eta.l Anti-inflammatory strategies in alcoholic steatohepatitis[J].J Gastroenterol Hepato,l 2007,22(Suppl1):S59-61
[2]Arteel G.Oxidants and antioxidants in alcohol-induced liver disease[J].Gastroenterology,2003,124(3):778-790
[3]Lieber CS.Alcoholic fatty liver:its pathogenesis and mechanism of progression to inflammation and fibrosis[J].Alcoho,l 2004,34(1):9-19
[4]Wu D,Cederbaum A.Oxidative stress mediated toxicity exerted by ethanol-inducible CYP2E1[J].ToxicolAppl Pharmaco,l 2005,207(2 Suppl):70-76
[5]McClain C,SongZ,Barve S,eta.l Recentadvances in alcoholic liv-er disease Ⅳ.Dysregulated cytokinemetabolism in alcoholic liverdis-ease[J].Am J PhysiolGastrointestLiver Physio,l 2004,287(3):G497-502
[6]Zhou Z,Wang L,Song Z,et a.l A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-α production[J].Am J Patho,1 2003,163(3):1137-1146
[7]YinM,WheelerMD,KonoH,eta.l Essential role of tumornecrosis factor-αin alcohol-induced liver injury[J].Gastroenterology,2004,10(4):1329-1332
[8]KharbandaKK,RogersDD,MailliardME,eta.l Role ofelevated S-adenosyhomocysteine in rat hepatocyte apoptosis:Protection by beta-ine[J].Bochem Pharmaco,1 2005,70(12):1883-1990
[9]ZHAO CY,J[ANGL,L I ZJ,et al.Peroxisome proliferator activated receptor2gamma in pathogenesis of experimental fatty liver disease[J].J Gasteroenterol,2004,10:1329-1332
[10]MACSWEEN RN,BURT AD.Histologic spect rum of al- coholic liver disease [J].Semin Liver Dis,1986,6:221-232
[11]FISHER M,YOU M,MATSUMOT O,et al.Peroxisome proliferator activated receptor alpha agonist treatment reverses PPAR alpha dysfunction and abnormali-ties in hepatic lipid metabolism in ethanol-fed mice[J].J Biol Chem,2003,278:27997-28004
[12]BYKOV I,JARVELAINEN H,L INDROS K L-Car-tinite alleviates alcohol induced liver damage in rats:Role of tumor necrosis factor-alpha[J].Alcohol Alcoholism,2003,38:400- 406
[13]GALL I AJ,PINAIRE M,FISCHER R,et al.The transcriptional and DNA activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol-induced fatty liver[J].J Biol Chem,2001,276:68-75
[14]王海霞,贾柳萍,陈其李,等.酒精性脂肪肝患者血脂水平与肝组织病理改变相关性的实验研究[J].国际消化病杂志,2006,26:211-212
[15]池晓玲,陈培琼,萧焕明,等.肝病治疗仪治疗酒精性脂肪肝82例临床观察[J].中国中医药信息杂志,2005,12:73
[16]姚希贤,南月敏,王莹,等.高脂高糖、饮酒建立家兔脂肪肝模型及超声量化诊断[J].世界华人消化杂志,2006,24:1484-1485
[17]赵虹,刘彬祥,张利中,等.CT定量诊断脂肪肝的实验室研究[J].中华放射学杂志,1997,31:836-838
[18]曹茜,刘连祥,吴晶,等.脂肪肝的MR诊断[J].实用放射学杂志,1997,13:6272628
[19]李玉华,姚华,徐菲莉,等.酒精性脂肪肝与非酒精性脂肪肝患者生化指标的对比分析[J].新疆医科大学学报,2005,28:392-393
[20]Sorbi D,Boynton J,lindor KD.The ratio of aspartate aminotransferase to alanine aminotransferase:potential value in differentiating nonalcoholic steatohepatitis from alocholic liver disease.AmJ Gastroenterol,1999,94:1018-1022
[21]司维柯.血清GG物测定现状与临床诊断价值[J].国外医学临床生物化学与检验学分册,1991,12:254-556
[22]张建华,杨文东,刘民.长期大量饮酒者肝功能和血脂检测指标变化的临床分析[J].实用诊断与治疗杂志,2006,20:258
[23]范建高.酒精性与非酒精性脂肪性肝病[J].中华肝脏病杂志,2003,11:692
[24]MERKEL C,MARCHESINI G,FABBRI A,et al.The course of galactosec elimination capacity in patients with alcoholic cirrhosis:possible use as a surrogate marker for death[J].Hepatology,1996,24:820-823
[25]LIBER CS,WEISS DG,GROSZMANN R,et al.Veterans Affiairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease:effects on drinking behavior by nurse/physician teams[J].Alcohol Clin Exp Res,2003,27:757- 1764
[26]MENDENHALL CL,ROSSSELLE GA,GARTSIDE P,et al.Relationship of protein calorie malnutrition to alco-holic liver disease:a reexamination of data from two Vet-erans Administration Cooperative Studies[J].Alcoholic Clin Exp Res,1995,19:635-641
[27]HIRSCH S,BUNOUT D,MAZA P,et al.Controlled trial on nutrition supplementation in outpatients with symp-tomatic alcoholic cirrhosis[J].JPEN J Parenter Enteral Nurr,1993,17:119-124
[28]KEARNS PJ,YOUNG H,GARCIA G,et al.Accelerated improvement of alcoholic liver disease with enteral nutri- tion[J].Gastroenterology,1992,102:200-205
[29] LAMBERT JC,ZHOU Z,WANG L,et al.Prevention of intestinal structural integrity by zincid independent of metallothionein in alcohol-intoxicated mice [J].AM J Pathol,2004,164:1959- 1966
[30] MATHURIN P,MENDENHALL CL,CARITHERS RL,etal. Corticosteroids improve shortterm survival in patients with severe alcoholic hepatitis(AH) individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH[J].J Hepatol,2002,36:480-487
[31] AKRIVIADIS E,BOTLA R,BRIGGS W,et al.Pentoxi-fylline improves short-term survival in severe acute alco-holic hepatitis: a double-blind, placebo-controlled trial [J]. Gastroenterology,2000,119:1637-1648
[32] TILG H,JALAN R,KASER A,et al.Anti-tumor necro-sis factor-alpha monoelonal antibody therapy in severe al-coholic hepatitis[J].J Hepatol, 2003,38:419-425
[33] MENON KV,STADHEIM L,KAMATH PS,et al.A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis[J]. Am J Gaxtroen-terol, 2004,99:255-260.
[34] MORGAN TR,NEMCHAUSKY N,SCHIFF E,et al Colchicine does not prolong life in patients with advanced alcoholic cirrhpsis: results of a prospective,ran-domized,placebocontrolled, multicenter VA trial[J] Gastroenterology ,2002,122:641
[35] CORTEZ-PINTOH,ALEXANDRINO P,CAMILO ME,et al.Lack of effect of colchicines in alcoholic cirrhosis: final results of a double blind randomized trial[J].Eur J Gastro-enterol Hepatol ,2002,14:377-381
[36] RAMBALDI A,IAQUINTO G,GLUUD,C,et al.Anaboli-ucandrogenic steroids for alcoholic liver disease: a ochrane review[J].Am J Gastroenterol,2002,97:1674-1681
[37] PARES A,PLANAS R,TORRES M,et al.Effects of si-lymarin in alcoholic patients with cirrhosis of the liver:results of a controlled, double-blind, randomized and multicenter trial[J]. J Hepatol, 1998,28:615-621
[38] LEE TD,SADDA MR,MENDLER MH,et al.Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis[J].Alcohol Clin Exp Res,2004,28:173-181
[39] SANCHEZ-GONGORAQ E,RUIZ F, MINGORANCE J,et al. Interaction of liver methionine adenosyltransferase with hydroxyl radical[J]. FASEB J, 1997,11:1013-1019
[40]SONG Z,MCCLAIN CJ,CHEN T,et al.S-adenosylmethionine protects against acetaminophen-induced hepatotoxitcity in mice[J].Pharmacology,2004,71:199-208
[41]MCCLAIN CJ,HILL DB,SONG Z,et al.S-adenosylmethionine,cytokines,and alcoholic liver disease[J].Alcohol,2002,27:185-192
[42]MATO JM,CAMARA J,FERNANDEZ DP,et al.S-adenosylmethionine in alcoholic liver cirrhosis:a randomized,placebo-controlled,double-blind,multicenter clinical trial[J].J Hepatol,1999,30:1081-1089
[43]MCCLAIN CJ,HILL D,KUGELMAS M,et al.Nutrition and liver disease:in Rm B:Present Knowledge in Nutrition[J].Washington,International Life Sciences Institute,2001,483-496
[44]HILL DB,DEVALARAJA R,JOSHI-BRAVE S,et al.Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells,in vivo[J].Clin Biochem,1999,32:563-570
[45]MEZEY E,POTTRER JJ,RENNIE-TANKERSLEY L,et al.A randomized placebo controlled trial of vitamin E for alcoholic hepatitis[J].J Hepatol,2004,40:40-46
[46]BJELAKOVIC G,NIKOLOVA D,SIMONETTI RG,et al.Antioxidant supplements for prevention of gastrointestinal cancers:a systematic review and meta-analysis [J].Lancet,2004,364:1219-1228
[47]MILLER ER,PASTOR-BARRIUSO R,DALAL D,et al.Meta-analysis:high-dosage vitamin E supplementation may increase all-cause mortality[J].Ann Inter Med,2005,142:37-46
[48]PENA LR,HILL DB,MCCLAIN CJ.Treatment with glutathione precursor decreases cytokine activity[J].JPEN J Parenter Enteral Nutr,1999,23:1-6
[49]HALSTED CH,VILLLANUEVA JA,DEVLIN AM,et al.Metabolic interactions of alcohol and folate[J].J Nutr,2002,132(suppl):1367S-2372S
[50]JI C,KAPLOWIZ N.Betaine decreases hyerhomocysteinemia,endoplasmic reticulum stress,and liver injury in alcohol-fed mice[J].Gastroenterology,2003,124:1488-1499
[51]纪宝华.非药物治疗对高血压、肥胖、糖尿病和脂质代谢异常的重要性-中华内科杂志,1998,37:293
[52]吴悦陶,王觉生,陈干仁-体育运动对轻度高血压病患者血胰岛素的影响·中华内科杂志,1998,37:298